The decision was based on findings from the Phase III PANOVA-3 clinical trial.

The MarketWatch News Department was not involved in the creation of this content. Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 ...

NovoCure Limited NVCR recently announced that its portable medical device, Option Pax, has received the CE (Conformité ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and ...

Novocure (NVCR 5.73%) and its international partner Zai Lab (ZLAB +2.55%) announced successful top-line results from the Panova-3 study on Dec. 2, 2024. In a nutshell, it showed that the company's ...

The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances ...

Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, ...